The results of this study were presented in the form of a Poster on May 12, 2011 at the 2011 Society of Biological Psychiatry Conference held in San Francisco, CA, May 12–14, 2011.
The authors thank research assistants Sarah Forrester and Clifford Workman for their assistance with this manuscript.
The images acquired from patients with Alzheimer’s dementia and mild cognitive impairment were supported by a methods development grant from GlaxoSmithKline awarded to Drs. Lyketsos and Albert. Dr. Lyketsos has received grant support (research or CME) from the following organizations: NIMH, NIA, Associated Jewish Federation of Baltimore, Weinberg Foundation, Forest, GlaxoSmithKline, Eisai, Pfizer, Astra-Zeneca, Lilly, Ortho-McNeil, Bristol-Myers, Novartis, National Football League, and Elan. Dr. Lyketsos has served as a consultant/advisor for AstraZeneca, GlaxoSmithKline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, Pfizer, Genentech, Elan, the NFL Players Association, NFL Benefits Office, and Avanir. Dr. Lyketsos has received honorarium or travel support from Pfizer, Forest, GlaxoSmithKline, and Health Monitor. The remaining authors have reported no biomedical financial interests or potential conflicts of interest. This research was funded in part by grants from GlaxoSmithKline, the National Institute on Aging (P50 AG005146, P50 AG021334, R21 AG033774), and the National Center for Research Resources (P41 RR15241).